Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00691652 · ClinicalTrials.gov registry record · Phase 1
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00691652: Clinical Trial Phase 1 study, sponsored by OHSU Knight Cancer Institute.
NCT00691652 is a Phase 1 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00691652, a Phase 1 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving clofarabine together with rituximab may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of clofarabine when given together with rituximab and to see how well they work in treating patients with relapsed B-cell non-Hodgkin lymphoma.
Primary Outcome
Initially, 3 patients will be enrolled into a dose level during the dose-escalation portion: * If no patient experiences dose-limiting toxicities during the first 4 weeks, then 3 patients will be enrolled into the next dose level. * If one of the three patients develops dose-limiting toxicities, then 3 additional patients will be enrolled in that cohort. If none of the additional 3 patients experiences dose-limiting toxicities, then further dose-escalation occurs. * If one additional patient ex
Interventions
- GENETIC gene expression analysis
- GENETIC microarray analysis
- BIOLOGICAL rituximab
- DRUG clofarabine
- GENETIC DNA methylation analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Why NCT00691652 stopped before completion
NCT00691652 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00691652 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00691652 about?
NCT00691652 is a clinical study titled "Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma". RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer ...
What is the current status of trial NCT00691652?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2008-05. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00691652?
The interventions under investigation include: gene expression analysis (GENETIC), microarray analysis (GENETIC), rituximab (BIOLOGICAL), clofarabine (DRUG), DNA methylation analysis (GENETIC).
Who is sponsoring clinical trial NCT00691652?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00691652's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia